Logo image of RYTM

RHYTHM PHARMACEUTICALS INC (RYTM) Stock Fundamental Analysis

USA - NASDAQ:RYTM - US76243J1051 - Common Stock

113.76 USD
+1.95 (+1.74%)
Last: 10/31/2025, 8:12:49 PM
113.76 USD
0 (0%)
After Hours: 10/31/2025, 8:12:49 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to RYTM. RYTM was compared to 534 industry peers in the Biotechnology industry. While RYTM seems to be doing ok healthwise, there are quite some concerns on its profitability. RYTM is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

RYTM had negative earnings in the past year.
In the past year RYTM has reported a negative cash flow from operations.
RYTM had negative earnings in each of the past 5 years.
In the past 5 years RYTM always reported negative operating cash flow.
RYTM Yearly Net Income VS EBIT VS OCF VS FCFRYTM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

RYTM has a Return On Assets of -50.55%. This is comparable to the rest of the industry: RYTM outperforms 49.63% of its industry peers.
The Return On Equity of RYTM (-141.04%) is worse than 61.98% of its industry peers.
Industry RankSector Rank
ROA -50.55%
ROE -141.04%
ROIC N/A
ROA(3y)-56.77%
ROA(5y)-52.61%
ROE(3y)-112.7%
ROE(5y)-88.62%
ROIC(3y)N/A
ROIC(5y)N/A
RYTM Yearly ROA, ROE, ROICRYTM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

RYTM has a better Gross Margin (89.25%) than 90.82% of its industry peers.
RYTM's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for RYTM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 89.25%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.35%
GM growth 5YN/A
RYTM Yearly Profit, Operating, Gross MarginsRYTM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

4

2. Health

2.1 Basic Checks

RYTM does not have a ROIC to compare to the WACC, probably because it is not profitable.
RYTM has more shares outstanding than it did 1 year ago.
The number of shares outstanding for RYTM has been increased compared to 5 years ago.
The debt/assets ratio for RYTM has been reduced compared to a year ago.
RYTM Yearly Shares OutstandingRYTM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
RYTM Yearly Total Debt VS Total AssetsRYTM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 13.85 indicates that RYTM is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 13.85, RYTM belongs to the top of the industry, outperforming 85.96% of the companies in the same industry.
RYTM has a Debt/Equity ratio of 0.79. This is a neutral value indicating RYTM is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.79, RYTM is doing worse than 74.34% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Altman-Z 13.85
ROIC/WACCN/A
WACC8.68%
RYTM Yearly LT Debt VS Equity VS FCFRYTM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

RYTM has a Current Ratio of 2.79. This indicates that RYTM is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.79, RYTM is doing worse than 66.48% of the companies in the same industry.
A Quick Ratio of 2.64 indicates that RYTM has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.64, RYTM is doing worse than 66.29% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.79
Quick Ratio 2.64
RYTM Yearly Current Assets VS Current LiabilitesRYTM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

7

3. Growth

3.1 Past

RYTM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.11%, which is quite impressive.
RYTM shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.34%.
The Revenue has been growing by 245.69% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)33.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.7%
Revenue 1Y (TTM)22.34%
Revenue growth 3Y245.69%
Revenue growth 5YN/A
Sales Q2Q%66.8%

3.2 Future

RYTM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.60% yearly.
The Revenue is expected to grow by 61.60% on average over the next years. This is a very strong growth
EPS Next Y31.72%
EPS Next 2Y24.06%
EPS Next 3Y30.38%
EPS Next 5Y31.6%
Revenue Next Year47.25%
Revenue Next 2Y54.37%
Revenue Next 3Y62.96%
Revenue Next 5Y61.6%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
RYTM Yearly Revenue VS EstimatesRYTM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
RYTM Yearly EPS VS EstimatesRYTM Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RYTM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RYTM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RYTM Price Earnings VS Forward Price EarningsRYTM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RYTM Per share dataRYTM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as RYTM's earnings are expected to grow with 30.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.06%
EPS Next 3Y30.38%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RYTM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RHYTHM PHARMACEUTICALS INC

NASDAQ:RYTM (10/31/2025, 8:12:49 PM)

After market: 113.76 0 (0%)

113.76

+1.95 (+1.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)11-04 2025-11-04/bmo
Inst Owners97.8%
Inst Owner Change0.46%
Ins Owners0.67%
Ins Owner Change0.46%
Market Cap7.56B
Revenue(TTM)156.29M
Net Income(TTM)-188402000
Analysts87
Price Target120.36 (5.8%)
Short Float %8.8%
Short Ratio9.75
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-11.01%
Min EPS beat(2)-13.18%
Max EPS beat(2)-8.85%
EPS beat(4)2
Avg EPS beat(4)-2.55%
Min EPS beat(4)-13.18%
Max EPS beat(4)11.07%
EPS beat(8)4
Avg EPS beat(8)-1.33%
EPS beat(12)7
Avg EPS beat(12)1.68%
EPS beat(16)10
Avg EPS beat(16)3.14%
Revenue beat(2)1
Avg Revenue beat(2)-5.75%
Min Revenue beat(2)-20.47%
Max Revenue beat(2)8.98%
Revenue beat(4)3
Avg Revenue beat(4)-1.17%
Min Revenue beat(4)-20.47%
Max Revenue beat(4)8.98%
Revenue beat(8)3
Avg Revenue beat(8)-2.24%
Revenue beat(12)5
Avg Revenue beat(12)0.92%
Revenue beat(16)8
Avg Revenue beat(16)14.5%
PT rev (1m)4.89%
PT rev (3m)13.85%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.8%
EPS NY rev (1m)0.17%
EPS NY rev (3m)-8.41%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)7.67%
Revenue NY rev (1m)0.27%
Revenue NY rev (3m)6.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 48.35
P/FCF N/A
P/OCF N/A
P/B 56.56
P/tB 59.11
EV/EBITDA N/A
EPS(TTM)-3.01
EYN/A
EPS(NY)-2.07
Fwd EYN/A
FCF(TTM)-1.62
FCFYN/A
OCF(TTM)-1.62
OCFYN/A
SpS2.35
BVpS2.01
TBVpS1.92
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -50.55%
ROE -141.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 89.25%
FCFM N/A
ROA(3y)-56.77%
ROA(5y)-52.61%
ROE(3y)-112.7%
ROE(5y)-88.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.35%
GM growth 5YN/A
F-Score4
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.79
Quick Ratio 2.64
Altman-Z 13.85
F-Score4
WACC8.68%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.7%
EPS Next Y31.72%
EPS Next 2Y24.06%
EPS Next 3Y30.38%
EPS Next 5Y31.6%
Revenue 1Y (TTM)22.34%
Revenue growth 3Y245.69%
Revenue growth 5YN/A
Sales Q2Q%66.8%
Revenue Next Year47.25%
Revenue Next 2Y54.37%
Revenue Next 3Y62.96%
Revenue Next 5Y61.6%
EBIT growth 1Y56.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year34.21%
EBIT Next 3Y29.52%
EBIT Next 5YN/A
FCF growth 1Y32.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y32.04%
OCF growth 3YN/A
OCF growth 5YN/A

RHYTHM PHARMACEUTICALS INC / RYTM FAQ

What is the fundamental rating for RYTM stock?

ChartMill assigns a fundamental rating of 3 / 10 to RYTM.


What is the valuation status for RYTM stock?

ChartMill assigns a valuation rating of 1 / 10 to RHYTHM PHARMACEUTICALS INC (RYTM). This can be considered as Overvalued.


How profitable is RHYTHM PHARMACEUTICALS INC (RYTM) stock?

RHYTHM PHARMACEUTICALS INC (RYTM) has a profitability rating of 2 / 10.


How financially healthy is RHYTHM PHARMACEUTICALS INC?

The financial health rating of RHYTHM PHARMACEUTICALS INC (RYTM) is 4 / 10.


What is the expected EPS growth for RHYTHM PHARMACEUTICALS INC (RYTM) stock?

The Earnings per Share (EPS) of RHYTHM PHARMACEUTICALS INC (RYTM) is expected to grow by 31.72% in the next year.